Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fine

Showing results (771-780 of 971) with videos related to

Pageof 98
Sort By:
The Canadian Journal of Cardiology|August 25, 2024
Factors Influencing Clinical Initiation of Tafamidis Therapy for Transthyretin Amyloidosis Cardiomyopathy: A Canadian Referral Center ExperienceKaran Shahi, Robert J H Miller, Steven Dykstra, et al.
Journal of Clinical Medicine|September 28, 2024
Baseline Predictors of Adverse Outcomes for Transthyretin Amyloidosis Cardiomyopathy Patients Treated and Untreated with Tafamidis: A Canadian Referral Center ExperienceKaran Shahi, Robert J H Miller, Steven Dykstra, et al.
Sexually Transmitted Diseases|November 30, 2005
Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infectionsJulius Schachter, Max A Chernesky, Dean E Willis, et al.
The American Journal of the Medical Sciences|March 13, 2010
Predictors of timely antibiotic administration for patients hospitalized with community-acquired pneumonia from the cluster-randomized EDCAP trialDouglas J Hsu, Roslyn A Stone, D Scott Obrosky, et al.
ESC Heart Failure|March 9, 2022
Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory riskRobert J H Miller, Majid Nabipoor, Erik Youngson, et al.
CJC Open|September 25, 2023
Right Ventricular Systolic Pressure Trajectory as a Predictor of Hospitalization and Mortality in Patients With Chronic Heart FailureGynter Kotrri, Erik Youngson, Nowell M Fine, et al.
Neurology|August 8, 2022
Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 TrialChadwick W Christine, R Mark Richardson, Elisabeth M Fine, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|October 4, 2021
Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosisGolnaz Roshankar, Geneva C White, Sebastien Cadet, et al.
British Journal of Urology|July 1, 1995
Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human renal cell tumour targets with potentiation by cis-diamminedichloroplatinum(II)J E Gold, T R Masters, B Babbit, et al.
The Oncologist|January 25, 2014
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imagingBrett Hughes, Linda Mileshkin, Peter Townley, et al.
Pageof 98

Showing results (771-780 of 971) with videos related to

Sort By:
Pageof 98
The Canadian Journal of Cardiology|August 25, 2024
Factors Influencing Clinical Initiation of Tafamidis Therapy for Transthyretin Amyloidosis Cardiomyopathy: A Canadian Referral Center ExperienceKaran Shahi, Robert J H Miller, Steven Dykstra, et al.
Journal of Clinical Medicine|September 28, 2024
Baseline Predictors of Adverse Outcomes for Transthyretin Amyloidosis Cardiomyopathy Patients Treated and Untreated with Tafamidis: A Canadian Referral Center ExperienceKaran Shahi, Robert J H Miller, Steven Dykstra, et al.
Sexually Transmitted Diseases|November 30, 2005
Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infectionsJulius Schachter, Max A Chernesky, Dean E Willis, et al.
The American Journal of the Medical Sciences|March 13, 2010
Predictors of timely antibiotic administration for patients hospitalized with community-acquired pneumonia from the cluster-randomized EDCAP trialDouglas J Hsu, Roslyn A Stone, D Scott Obrosky, et al.
ESC Heart Failure|March 9, 2022
Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory riskRobert J H Miller, Majid Nabipoor, Erik Youngson, et al.
CJC Open|September 25, 2023
Right Ventricular Systolic Pressure Trajectory as a Predictor of Hospitalization and Mortality in Patients With Chronic Heart FailureGynter Kotrri, Erik Youngson, Nowell M Fine, et al.
Neurology|August 8, 2022
Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 TrialChadwick W Christine, R Mark Richardson, Elisabeth M Fine, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|October 4, 2021
Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosisGolnaz Roshankar, Geneva C White, Sebastien Cadet, et al.
British Journal of Urology|July 1, 1995
Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human renal cell tumour targets with potentiation by cis-diamminedichloroplatinum(II)J E Gold, T R Masters, B Babbit, et al.
The Oncologist|January 25, 2014
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imagingBrett Hughes, Linda Mileshkin, Peter Townley, et al.
Pageof 98